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Trends in Secondary Prevention of Coronary Heart Disease in
Tunisia: Prevention of Recurrences of MI and Stroke
N. Ben Mansour, O. Lassoued, O. Saidi, W. Aissi, S. Ben Ali, H. Ben Romdhane
Tunis, TunisiaThis work
From the L
(nadiabmy@O B J E C T I V E S The survival beneﬁts achieved by prescription of antiplatelet agents, B-adrenoreceptor
antagonists (beta-blockers), angiotensin II receptor blockers (ARB), and lipid lowering agents in patients
surviving the myocardial infarction (MI) have been well documented in large clinical trial. Despite well-
established beneﬁts, these pharmacological agents continue to be underutilized. The main objective of
this study was to evaluate the progress of cardiovascular secondary prevention practices in Tunisia.
ME THOD S The PREMISE (Prevention of Recurrence of Myocardial Infarction and Stroke) is
a descriptive, cross-sectional study conducted in Tunisia in two phases (2002 and 2009). Seven hundred
eighty two patients were recruited. The recruitment criteria were: previous MI, stable angina, unstable
angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG),
stroke, transient ischemic attack (TIA) or carotid endarterectomy. This analysis is limited to coronary heart
disease (CHD) patients. Five hundred hospital patients were interviewed and their medical records were
reviewed: 250 in 2002 and 250 in 2009. Patients were included if they had conﬁrmed diagnosis of MI,
angina, CABG or PTCA, and if their ﬁrst cardiovascular event had occurred more than one month but not
later than 3 years ago. We compared the total of both patient groups, using the prevalence of Cardio-
Vascular Risk Factors (CVRF) and the treatment prescribed at hospital discharge.
R E S U LT S The proportion of patients with reported hypertension, diabetes, hypercholesterolemia
and current smoker patients had decreased. Concerning pharmacological prescriptions, a signiﬁcant
increase was observed in prescribing statins (38.9% vs. 70.3%) and ACE inhibitors (49.3% vs. 69.9%), non
pharmacological prescriptions as healthy diet or tobacco cessation had opposite trends. Adherence to
treatment did not change substantially.
CON C L U S I O N Although the use of cardioprotective drugs had increased in CHD patients, there
are still gaps in secondary prevention in Tunisia. The recommended strategies of secondary prevention
need to be applied more intensively in clinical practice.Tunisia is now facing a rapidly growing burden
of chronic disease. The epidemiological transition
has been compounded by powerful environmental
and behavioral changes. In particular, the adoption
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all lead to increases in major cardiovascular disease
risk factors [1]. Cardiovascular diseases (CVD) are
responsible for 30% of all deaths worldwide [2].
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362past years among patients in the United States and
in Europe [3,4]. This decline in mortality of CVD
has been attributed to advances in the prevention
and treatment of acute and chronic ischemic heart
disease. In the Tunisian population, the age-
standardized rate of myocardial infarction (MI)
was 163 per 100,000 people [5]. It has been re-
ported that in persons with a history of MI, cardio-
vascular mortality in absence of treatment was high,
5% per year after a ﬁrst MI, and 10% per year after
a subsequent MI, persisting for many years and
probably for the rest of the patient’s life. The high
mortality rate emphasizes the need to ensure that
everyone who had an MI, even in previous years,
receives effective preventive treatment [6].
The survival beneﬁts achieved by prescription of
antiplatelet agents, beta-adrenoreceptor antagonists
(beta-blockers), angiotensin-converting enzyme
(ACE) inhibitors, and lipid-lowering agents in
patients surviving MI have been well documented
in large clinical trials. There is consensus that
patients with a history of MI should be treated
with a combination of these drugs [7]. When the
potential beneﬁts of quitting smoking and of
lowering blood pressure in hypertensive patients
are added to the 4-drug regime, it may be possible
to lower the risk of future events in high-risk indi-
viduals by more than four-ﬁfths [8]. Despite the
positive ﬁndings of studies delineating the effective-
ness of these therapies, ﬁndings of several previous
studies suggest that these medications are underpre-
scribed to patients at hospital discharge after MI
even in developed countries [9].
In low- and middle-income countries, there is a
scarcity of data related to the secondary prevention
of CVD. In this context, the World Health Organi-
zation (WHO) has initiated the WHO-PREMISE
(Prevention of Recurrences of MI and Stroke)
program to provide technical cooperation to coun-
tries for assessing and scaling up secondary preven-
tion of CVD [10]. In Tunisia, the PREMISE study
was conducted in 2 phases (2002 and 2009). This
study aimed to provide an opportunity to view
time trends over almost a practice of secondary
prevention in patients with CVD in Tunisia.
METHODS
Study population. TheWHO-PREMISE study is a
descriptive, cross-sectional investigation. In Tunisia,
the PREMISE study was conducted in 2 phases
(2002 and 2009) on patients followed in the outpa-
tient cardiology departments of university hospitals inthe district of Tunis. The ﬁrst study took place in 5
centers and the second in 4 centers. For the analysis,
only common hospitals were considered.
A total of 782 patients were recruited (279 in
2002 and 503 in 2009). The recruitment criteria
were: previous MI, stable angina, unstable angina,
percutaneous transluminal coronary angioplasty
(PTCA), coronary artery bypass graft (CABG),
stroke, transient ischemic attack, or carotid endar-
terectomy. This study dealt with 500 coronary heart
disease (CHD) patients. The recruitment criteria
were patients (both sexes) with conﬁrmed diagnosis
of CHD deﬁned by 1 or more of the following
conditions: MI, angina, CABG, or PTCA. Patients
were included if their ﬁrst cardiovascular event had
occurred more than 1 month but not later than
3 years earlier.
During a period of 6 months (in 2002e2009),
and after obtaining informed consent from the
patients, interviews were conducted by trained
doctors using a standardized questionnaire. The
following data were collected: demographic and
personal details, exposure to risk factors (except
obesity), treatments prescribed and adherence to
treatment, perceived barriers, access to care, and
availability and affordability of drugs.
The presence of MI, angina, CABG, or PTCA
was self-reported but also conﬁrmed by checking
physician hospital discharge reports. Risk factors
were self-reported too; neither measurements of
blood pressure nor blood tests were carried out.
Patients reporting being hypertensive, dyslipidemic,
diabetics or who were receiving antihypertensive
drugs, lipid-lowering agents, and antidiabetic medi-
cation (oral antidiabetic drugs or insulin) were classi-
ﬁed as having hypertension, dyslipidemia, and
diabetes, respectively. All the participants were asked
if a healthy diet had been prescribed to them. The
prescription of tobacco cessation was asked only to
patients who still smoked (at least 1 cigarette daily)
after CHD occurred. The status of “physically active”
was considered to be 30 min or more of physical
activity daily. The drug prescription was veriﬁed by
inspecting tablets, past prescriptions, and medical
records. Patients with prescriptions were asked
whether they had adhered (over the last month) to
the prescribed drugs.
Statistical analysis. All statistical analyses were con-
ducted using the SPSS statistical package (version
15.0, SPSS Inc., Chicago, Illinois). The signiﬁcance
threshold was set at P < 0.05. Continuous variables
are presented as mean  SD. Relative frequencies
were derived for qualitative variables. Differences
Table 1. Diagnosis and risk-factors prevalence (2002e2009)
2002 (%) 2009 (%) P Value OR (95% CI)
Diagnosis
MI 49.6 59.2 0.019 1.47 (1.03e2.10)
UA 49.6 44.4 <0.001 0.49 (0.34e0.71)
CABG or PTCA 28.4 48.0 <0.001 2.32 (1.60e3.37)
Risk factors
Hypertension 59.3 51.4 0.08 0.72 (0.50e1.04)
Diabetes 54.8 46.0 0.05 0.70 (0.49e1)
Dyslipidemia 50.6 31.2 <0.001 0.44 (0.30e0.63)
Current smokersa 17.0 12.9 0.201 0.43 (0.29e0.62)
Physical activityb 43.5 30.4 0.003 0.56 (0.39e0.82)
Three or more RFc 61.4 59.6 0.70 0.92 (0.63e1.34)
CABG, coronary artery bypass graft; CI, conﬁdence interval; MI, myocardial infarction; OR, odds ratio; PTCA, percutaneous transluminal coronary angioplasty; RF, risk
factor(s); UA, unstable angina.
a One cigarette or more daily.
b Thirty min or more of physical activity daily.
c Association of 3 or more of the risk factors already cited.
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Fig. 1. The prevalence of treatments prescribed indepen-
dently. ACE, angiotensin-converting enzyme.
G L O B A L H E A R T , V O L . 7 , N O . 4 , 2 0 1 2 Ben Mansour et al.
D e c e m b e r 2 0 1 2 : 3 6 1 - 3 6 6
Trends in Secondary Prevention of Coronary Heart Disease
363in baseline characteristics between groups were
analyzed by Student t test and chi-squared test for
continuous variables and categorical variables,
respectively.
Multivariate analysis using logistic regression was
performed to adjust for potential confounding
factors.
R E SU L T S
In the PREMISE studies, 500 hospital patients
were interviewed and their medical records were
reviewed: 250 in PREMISE I and 250 in
PREMISE II. The distribution of patients by the
4 considered university hospitals was statistically
different between the 2 periods. Patients followed
in centers 1 and 2, respectively (32.0% vs. 42.4%)
and (27.2% vs. 35.6%), are over-represented in
2009 to the detriment of the others.
A signiﬁcant increase in the average age
(61.5  10.2 years vs. 63.7  10.3 years) was found
between the 2 studies, but the difference did not
persist when dividing the variable age in 3 classes
(<50, P50 and #60, >60). The percentage of
women signiﬁcantly increased (27.2% vs. 46.4%).
The proportion of patients who paid all of the costs
of their health care increased (1.2% vs. 17.8%). The
mean of total number of schooling years did not
vary (4.14 years vs. 4.77 years).
The diagnosis and the cardiovascular risk factors,
by year of study, are illustrated in Table 1. The
increases in the percentage of patients with MI
(49.6% vs. 59.3%) and those with a history of
CABG or PTCA (28.4% vs. 48.0%) were signiﬁ-
cant. Surprisingly, the proportion of patients withunstable angina decreased over time. Concerning
the prevalence of risk factors, the proportion of
patients reported as hypertensive, diabetic, hyper-
cholesterolemic, and current-smoker decreased.
However, inactive patients were more frequent
(56.5% vs. 69.6%). Almost 60% of patients (in
both studies) had 3 or more of these associated
risk factors in both studies.
The prevalence of the 4 different treatments
(aspirin, beta-blockers, ACE inhibitors, statins)
prescribed independently is presented by year of study
in Figure 1. The prescription of ACE inhibitors and
Men
p=0.08
2002 2009
Women
22%
44%
78%
56%
Fig. 2. The proportion of patients being on all 4 therapies by
sex.
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Fig. 4. The prevalence of nonpharmacological prescriptions.
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(OR) showed strong associations (OR: 2.38, 95%
conﬁdence interval [CI]: 1.63e3.47 for ACE inhib-
itors; OR: 3.72, 95% CI: 2.52e5.48 for statins), this
increase concerned men as well as women. The
prevalence of being on all 4 recommended therapies
also changed widely for the better (7.2% in 2002 vs.
38% in 2009 [P < 0.001], OR: 7.89, 95% CI:
6.04e10.17), but because of the sex-related opposite
trends of prescription and the decreased proportion
of men in 2009, the association was no longer signif-
icant (P ¼ 0.08) after stratifying by sex (Fig. 2).
Despite the increase of prescriptions, adherence to
treatments did not change substantially (Fig. 3).
Concerning nonpharmacological prescriptions, such
as healthy diet and tobacco cessation, an unexpected
decrease (P < 0.001) is shown in Figure 4.
Multivariate analysis of data from PREMISE I
showed only hypercholesterolemia as a predictor of0
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Fig. 3. The prevalence of adherence to treatments. Abbrevia-
tion as in Figure 1.better adherence to statins (OR: 4.8, 95% CI:
1.29e17.87).
D I S CU S S I ON
Though numerous randomized trials and observa-
tional surveys have shown the efﬁcacy of several
classes of drugs in secondary prevention for CHD,
little is known about the way current recommenda-
tions translate into real-life clinical practice [11].
This study is the ﬁrst conducted in Tunisia, in
which we aimed to gain an overview of how the
recommendations are implemented in university
hospitals and to evaluate both the progress and
the barriers to the secondary prevention of CHD
in this country.
Mortality associated with a recurrent acute MI is
appreciably higher than that associated with a ﬁrst
MI, and this is in spite of the existence of several
medications that have been shown to reduce the
likelihood of recurrent MI and death in patients
who have had an established MI [12].
The effectiveness of therapy with aspirin, beta-
blockers, ACE inhibitors, and lipid-lowering medi-
cations in the secondary prevention of MI has been
well established in large, randomized clinical trials
and/or meta-analyses of the published literature. It
has been estimated that use of these medications
can reduce the risk of cardiovascular death and
nonfatal reinfarction, respectively, by 13% and
31% for aspirin, by 22% and 27% for beta-
blockers, 21% and 25% for ACE inhibitors, and
14% and 25% for all lipid-lowering medications
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365combined. Statins prescribed alone reduce the risk
of recurrence by 24% [12,13]. According to these
results, the prescription of cardioprotective drugs
had increased in the last decade. For example, the
French PREVENIR (Prevent) study revealed
increased prescription rates for MI patients on
discharge for treatment with beta-blockers, ACE
inhibitors, and hypolipidemics [11]. In the Spanish
PREVESE (Prevención Secundaria del Infarto de
Miocardio en España) study, conducted in 1998
and 2002, despite the decrease in beta-blockers
prescription, an increase in the prescription of hypo-
lipidemics was observed [14].
Recent data from studies in Europe and the
United States suggest that there are still signiﬁcant
gaps in secondary prevention even in developed coun-
tries [9,10,14]. Data from REACH (Reduction of
Atherothrombosis for Continued Health Registry),
which collected its data during 2003 and 2004 [15],
underlie a gap between recommendations and prac-
tices especially for statins. Despite an overwhelming
amount of data in support of statins, the use of this
class of medicine was suboptimal (69.4%). In the
EUROSPIRE III (European action on secondary
prevention through intervention to reduce events)
survey carried out in 2006 and 2007, 93.2% of
patients with atherosclerotic manifestations were
using antiplatelet treatment, 85.5% beta-blockers,
and 88.8% lipid-lowering drugs [9]. Data from
a Finnish countrywide study showed that in 2003
about 28% and 15% of the patients did not receive
hypolipidemic medications or beta-blockers, respec-
tively, after their ﬁrst cardiovascular event [16].
Our results were generally in line with these large
international studies and showed that the use of
evidence-based medications in 2009 in Tunisia
was comparable to Western capitalist countries in
the beginning of the decade. Despite the signiﬁcant
increase in prescription of ACE inhibitors and sta-
tins during the study period, in 2009, about 30.1%
and 29.7% of the patients did not receive ACE
inhibitors and statins, respectively, after CHD
occurred. Although prescription of all medications
after CHD had increased over time, surprisingly
nonpharmacological prescriptions such as a healthy
diet or tobacco cessation had opposite trends. It is
clear now that drug treatments alone are not sufﬁ-
cient and must be combined with a professional life-
style intervention. Therapeutic lifestyle changes in
conjunction with an aggressive multidrug regimen
targeted toward the normalization of the major
risk factors will reduce vascular inﬂammation and
markedly decrease the risk of adverse cardiovascularevents and the need for revascularization proce-
dures. Effectively, a physician’s advice to stop
smoking is the most important ﬁrst step in the
cessation process, but this advice should be reiter-
ated and reinforced by all health professionals [17].
Concerning the prevalence of risk factors,
atherothrombotic patients worldwide had similar
risk-factor proﬁles: hypertension (81.8%); hypercho-
lesterolemia (72.4%); diabetes (44.3%); smoking
(14.4%); overweight (37.1%); obesity (26.6%);
morbid obesity (30.6%). Furthermore, 53.9% have
3 or more risk factors [15].
Study limitations. Our ﬁndings seem to be different,
particularly inferior to those of REACH registry,
concerning hypertension, diabetes, and hypercholes-
terolemia. Thismay be due to one of the limitations of
this study: we counted only self-reported risk factors,
sowe have omitted the unknownones. Fewer patients
also reported being smokers (12.9%) than in the
REACH registry, and this may be related to a
generally lower prevalence of smoking in our country,
but the comparison is difﬁcult because we did not
adjust for sex and age. It should be recognized also
that the study had some other limitations in terms of
its generalizability. In fact, the data do not represent
national proﬁles and therefore should not be used for
comparison between different countries. Sampling
patients from outpatient cardiology of university
hospitals in the district of Tunis introduces a selection
bias. The situation regarding secondary prevention of
CHD in the general population and among patients
who attend primary care facilities is likely to be far
worse than in our sample. Furthermore, the increase
of the prescription of ACE inhibitors and statins
must be considered with caution, because of the
over-representation in 2009 of patients followed in
2 hospitals to the detriment of the other patients.
The improvement could be partly explained by
a better application of recommendations in these
centers of care.
Despite these limitations, the study provides
a useful insight into current practice with regard
to secondary prevention.
Although the use of cardioprotective drugs had
increased in CHD patients, there are still gaps in sec-
ondary prevention in Tunisia. This could have several
causes, such as lack of implementation of evidence-
based clinical practice by healthcare providers [18],
unaffordability and unavailability of medications, and
selective prescription of drugs to certain categories of
patients among others [19]. However, a more system-
atic and widespread application of proven medical
therapies, reaching 80% of eligible patients, would
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Audit resources are limited, and prioritization is essen-
tial. Future local audit activity should therefore initially
focus on secondary prevention.
CONC LU S I ON S
There is a clear need to increase access to preven-
tive drug therapy through the development ofeffective national drug policies, rational- and
evidence-based selection of medicines, and afford-
able prices. Providing continuing medical education
to healthcare providers could also ensure that
patients beneﬁt fully from available knowledge
regarding secondary prevention. An effective infor-
mation system such as a coronary heart registry is
crucial for evaluating the performance of secondary
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